rabbit anti human phospho her2 erbb2 tyr1221 1222  (Cell Signaling Technology Inc)

Journal: Cancers

Article Title: Characterization of HER2-Positive Murine Breast Cancer Models for Investigating HER2-Targeted Therapy and Immunotherapy

doi: 10.3390/cancers18060997

Figure Lengend Snippet: Validation of HER2 expression in the newly established HER2-positive mouse tumors. ( A ) Western blotting analysis of HER2 and phosphor-HER2 in transduced 4T1 and EO771 cell lines. BT474 included as HER2+ control. ( B ) Representative immunofluorescence staining of HER2 expression in transduced EO771 cells. ( C ) Tumor volume curve of 4T1 ( top ) and EO771 ( bottom ) HER2-OE lines (n = 4–5 per group). Data is mean ± SD. ( D ) Representative immunohistochemistry staining of HER2 expression on tumor slices. The uncropped blots are included in .

Article Snippet: Briefly, for IF, cells grown in 96-well plates were fixed with 10% formalin for 30 min at room temperature and blocked with 1% BSA in PBS for 1 h. Cells were incubated overnight at 4 °C with primary rabbit anti-human HER2 antibody (Cell Signaling Technology, 2242S, 1:100 dilution), followed by incubation with Cy5-conjugated goat anti-rabbit secondary antibody (Jackson ImmunoResearch, West Grove, PA, USA, 711-175-152, 1:200) for 1 h at room temperature in the dark.

Techniques: Biomarker Discovery, Expressing, Western Blot, Control, Immunofluorescence, Staining, Immunohistochemistry

Journal: Cancers

Article Title: Characterization of HER2-Positive Murine Breast Cancer Models for Investigating HER2-Targeted Therapy and Immunotherapy

doi: 10.3390/cancers18060997

Figure Lengend Snippet: Trastuzumab alone was not able to reduce primary tumor size but decreased tumor brain metastasis in 4T1-HER2 models. ( A ) Tumor volume curve of 4T1-GFP, -HER2 WT , and -HER2 YVMA tumors treated with either saline or trastuzumab (15 mg/kg, IV). Filled shapes represent saline-treated groups; open shapes represent trastuzumab-treated groups. No statistically significant difference was observed between groups (repeated measures ANOVA p = 0.56). ( B ) Plot of average radiance from GFP fluorescence in the brains of 4T1 tumor-bearing mice. Symbols represent individual mice. ( C ) Fluorescence images of the brains of 4T1 tumor-bearing mice. TRA, trastuzumab. Data is shown as mean ± SD. Two-way ANOVA with Tukey’s HSD test was used in ( B ). *, p < 0.05; **, p < 0.01; ***, p < 0.001.

Article Snippet: Briefly, for IF, cells grown in 96-well plates were fixed with 10% formalin for 30 min at room temperature and blocked with 1% BSA in PBS for 1 h. Cells were incubated overnight at 4 °C with primary rabbit anti-human HER2 antibody (Cell Signaling Technology, 2242S, 1:100 dilution), followed by incubation with Cy5-conjugated goat anti-rabbit secondary antibody (Jackson ImmunoResearch, West Grove, PA, USA, 711-175-152, 1:200) for 1 h at room temperature in the dark.

Techniques: Saline, Fluorescence

Journal: Cancers

Article Title: Characterization of HER2-Positive Murine Breast Cancer Models for Investigating HER2-Targeted Therapy and Immunotherapy

doi: 10.3390/cancers18060997

Figure Lengend Snippet: HER2-targeted therapy synergizes with immunotherapy in HER2-overexpressing (OE) tumors. ( A ) Tumor volume ( left ) and survival ( right ) curves for EO771-HER2 YVMA and 4T1-HER2 YVMA models treated with saline, anti-HER2 agents (TRA + TUC), ICB (αPD-1 and αCTLA-4), or combination therapy (anti-HER2 + ICB) as indicated by arrows. ( B , C ) Flow cytometry quantification of CD4+ ( B ) and CD8+ ( C ) T cells in EO771-HER2 YVMA tumors on day 5. Mantel–Cox logrank test was used for survival analysis in ( A ). Two-way ANOVA with Bonferroni correction for multiple comparisons was used for ( B , C ). All data are shown as mean ± SD; * p < 0.05; ** p < 0.01.

Article Snippet: Briefly, for IF, cells grown in 96-well plates were fixed with 10% formalin for 30 min at room temperature and blocked with 1% BSA in PBS for 1 h. Cells were incubated overnight at 4 °C with primary rabbit anti-human HER2 antibody (Cell Signaling Technology, 2242S, 1:100 dilution), followed by incubation with Cy5-conjugated goat anti-rabbit secondary antibody (Jackson ImmunoResearch, West Grove, PA, USA, 711-175-152, 1:200) for 1 h at room temperature in the dark.

Techniques: Saline, Flow Cytometry

Journal: Cancers

Article Title: Characterization of HER2-Positive Murine Breast Cancer Models for Investigating HER2-Targeted Therapy and Immunotherapy

doi: 10.3390/cancers18060997

Figure Lengend Snippet: HER2-overexpressing models show differential responses to T-DM1 and T-Dxd. Tumor volume curves for BT474 (human HER2+) ( A ), HER2− MDA-MB-231 (human TNBC) ( B ), 4T1-HER2 WT ( C ), and EO771-HER2 WT ( D ) treated with saline (black line), T-DM1 (blue line), or T-Dxd (red line). n = 3 per group. * p < 0.05.

Article Snippet: Briefly, for IF, cells grown in 96-well plates were fixed with 10% formalin for 30 min at room temperature and blocked with 1% BSA in PBS for 1 h. Cells were incubated overnight at 4 °C with primary rabbit anti-human HER2 antibody (Cell Signaling Technology, 2242S, 1:100 dilution), followed by incubation with Cy5-conjugated goat anti-rabbit secondary antibody (Jackson ImmunoResearch, West Grove, PA, USA, 711-175-152, 1:200) for 1 h at room temperature in the dark.

Techniques: Saline